Skin regeneration composition and use thereof in skin treatment

Abstract

The present invention provides a composition for skin regeneration. The composition comprises a moisturizing agent, an antibacterial agent, a polyol, and an activator. The present invention also provides a method for preparing the composition and uses of the composition in preparing a drug for treating wounds, in preparing a skin regeneration product, and in preparing a medical cosmetic product. Correspondingly, the present invention also provides a cosmetic method for achieving scarless wound healing of the skin, comprising administering the composition of the present invention to a wound.

Description

Skin regeneration compositions and their use in treating skin

[0001] Cross-reference to related applications

[0002] This application claims priority to Chinese Patent Application No. CN202410711120.6, entitled “Skin Regeneration Composition and Its Use in Treating Skin”, filed on May 28, 2024 with the State Intellectual Property Office of China, the entire contents of which are incorporated herein by reference. Technical Field

[0003] This invention relates to the field of skin regeneration, and more specifically to compositions for achieving scarless healing of skin wounds. The invention also relates to the use of said compositions in the preparation of medicaments for achieving scarless healing of skin wounds, in the preparation of skin regeneration products, and in the preparation of medical aesthetic products. Background Technology

[0004] As the largest organ in the body, the skin consists of the lower endothelium (dermis) and the outer epithelium (epidermis). The skin's basic function is to act as a protective barrier against the external environment. However, when skin damage reaches a certain limit, it can easily leave wounds that are difficult to repair, such as burns, scalds, surgical incisions, and skin infections. In real life, burns, scalds, traffic accidents, and mechanical injuries occur frequently. Minor wounds can heal with medication or other means, but in more serious cases, damage to the dermis may require skin grafting. This results in noticeable scarring at the graft site, the donor site, and even at the site of spontaneous healing.

[0005] The primary goal of skin wound treatment is rapid healing and functional restoration, while minimizing scar area and restoring aesthetics. The process of restoring tissue integrity after injury is a fundamental and important function formed during phylogeny, namely the host's innate immune response. Unlike lower vertebrates, which can reconstruct damaged tissues, higher vertebrates rapidly repair and form fibrotic scars. Whether caused by trauma, microbial infection, or foreign substances, a series of events occur in an overlapping manner over time, including coagulation, inflammation, epithelial regeneration, formation of granulation tissue, matrix, and tissue remodeling. The repair process is mainly mediated by molecular signals, primarily cytokine interactions, which can activate and regulate cell activity to increase many times over, illustrating the importance of inflammation and healing. Post-injury responses are often studied by constructing skin models (1), and the cellular events and transient regulatory patterns of mediating factors after most tissue injuries are similar to those in the skin. The initial stage of injury triggers coagulation, followed by a local acute inflammatory response, then mesenchymal cell enrichment and proliferation, and matrix synthesis. Improper treatment of inflammation can lead to chronic, non-healing wounds, and uncontrolled matrix accumulation (often containing various cytokine pathways) can result in additional scarring and fibrosis.

[0006] Rapid repair and restoration of tissue integrity after injury is crucial for individual survival. In adult mammals and humans, wounds typically heal through the formation of fibrotic scars. Scars not only affect a patient's appearance but can also cause functional impairments and even deformities, resulting in severe psychological and physiological suffering. If such scars appear on exposed areas like the face and neck, they can negatively impact appearance and lead to feelings of inferiority. Therefore, developing a product that promotes scarless, regenerative wound healing is extremely important.

[0007] Currently, there are two main skin regeneration technologies. One is skin cell culture: cell culture involves taking cells from the body's tissues, simulating the in vivo environment, and allowing them to grow and multiply under sterile, appropriate temperature, pH, and nutritional conditions, while maintaining their structure and function. Currently, cell culture is also used to culture and expand autologous or allogeneic skin cells for skin transplantation in cases of large-area burns or severe injuries. However, this technology has drawbacks such as susceptibility to bacterial or fungal contamination, difficulty in controlling culture conditions, and a complex and costly process. Furthermore, these cultured cells can trigger an immune response after being introduced into the body, preventing true scar-free healing. The other technology is limb regeneration. Harvard University conducted experiments on frog leg regeneration. In this experiment, researchers first placed a silicone bioreactor containing drugs and hydrogel at the site of the frog's severed limb. The wound was exposed to the drugs for a certain period, and the in vitro administration of the drugs caused mature cells in the body to dedifferentiate into pluripotent stem cells (called "budding" stem cells). However, the experiment did not result in complete limb regeneration; instead, scar healing occurred.

[0008] In addition, the use of medical dressings has also been considered. In 1962, British scientist Dr. George Winter discovered that a moist environment is conducive to wound healing. Since then, various forms of moist dressings based on this idea have been widely developed, including hydrocolloid dressings and hydrogel dressings. Hydrogel dressings have advantages such as significantly relieving pain, absorbing large amounts of wound exudate, being breathable and moisturizing, and being transparent enough to allow observation of wound healing. Therefore, they have received widespread attention from researchers and developers worldwide. Moist dressings can provide a moist environment for wounds on the basis of traditional dressings, thereby accelerating wound healing. Based on moist dressings, various functional dressings have been developed, including dressings containing traditional Chinese medicine hemostatic and chemical anti-inflammatory ingredients, as well as biological moist dressings such as silver ion dressings. For large wounds and large exudates, negative pressure drainage products are needed. Chinese invention patent CN103691010B provides a specific preparation method for negative pressure drainage products; Chinese invention patent application CN105107015A discloses a preparation method for an antibacterial and healing-promoting biological foam dressing; Chinese invention patent application CN105169455A provides a burn and scald external emergency medical dressing and its preparation method.

[0009] Despite the rapid development of wet dressings, scarring is still inevitable in the process of accelerating wound healing. It is well known that once a scar forms, it is very difficult to remove. Therefore, another product category has emerged: scar removal products. Most of these products contain silicone components. For example, Chinese invention patent application CN201710253038.3 discloses a scar-removing silicone gel and its preparation method; Chinese invention patent application CN201610794712.4 discloses a self-packaged medical silicone gel scar patch and its manufacturing process; and Chinese invention patent application CN201510883010.9 discloses a human-like collagen scar repair silicone gel. These technologies use silicone gel in dressings, but they target the treatment of scar formation, and their effects are not ideal.

[0010] Therefore, there is an unmet need in existing technologies for scarless healing of skin wounds, and there is an urgent need for a product that can effectively promote skin regeneration while not forming scars or forming virtually no scars (i.e., achieving "scarless healing"). Summary of the Invention

[0011] During numerous experiments, the inventors unexpectedly discovered that compositions containing the following components are effective for skin regeneration and can achieve scarless healing:

[0012] A. A humectant, preferably selected from any one or any combination thereof, such as carrageenan, xanthan gum and konjac gum;

[0013] B. Antibacterial agent, preferably selected from chlorhexidine acetate and chitosan or any combination thereof;

[0014] C. Polyol, preferably selected from any one or any combination thereof of glycerol, mannitol and sorbitol, for example, selected from glycerol and mannitol;

[0015] D. Activator, selected from either honey or glucose, or any combination thereof, preferably honey or glucose.

[0016] Accordingly, in a first aspect of the invention, a composition for skin regeneration is provided, comprising the following components:

[0017] A. Humectants, including carrageenan, xanthan gum and konjac gum;

[0018] B. Antibacterial agents, including chlorhexidine acetate and chitosan;

[0019] C. Polyols, including glycerol, mannitol and sorbitol; or containing glycerol and mannitol;

[0020] D. Activator, selected from either honey or glucose, or any combination thereof, such as honey or glucose.

[0021] Using the composition of the present invention, scarless healing of the skin can be achieved, and the resulting skin has the same function as normal skin.

[0022] The composition of this invention is used for skin regeneration, eliminating the need for in vitro stem cell infusion during the regeneration process and thus avoiding the problem of stem cell carcinogenesis. This invention is simple, effective, and allows for control of the entire skin regeneration process from outside the body.

[0023] In some embodiments of the present invention, the humectant comprises carrageenan, xanthan gum, and konjac gum. In some embodiments of the present invention, the humectant constitutes 0.1% to 5.0% of the composition by weight, for example, 0.1% to 5.0%, 0.2% to 4.0%, 0.3% to 3.0%, 0.5% to 3.0%, 0.6% to 2.5%, or 0.8% to 2.0%. In some embodiments of the present invention, the humectant in the illustrated composition comprises the following components in parts by weight: 0.05-0.35 parts carrageenan, 0.20-0.60 parts xanthan gum, and 0.05-0.55 parts konjac gum, for example, 0.10-0.30 parts carrageenan, 0.25-0.55 parts xanthan gum, and 0.07-0.50 parts konjac gum, for example, 0.15-0.25 parts carrageenan, 0.32-0.48 parts xanthan gum, and 0.1-0.45 parts konjac gum.

[0024] In some embodiments of the invention, the antimicrobial agent comprises chlorhexidine acetate and chitosan. In some embodiments of the invention, the antimicrobial agent accounts for 0.05% to 2.0% of the composition by weight, for example, 0.1% to 1.5%, 0.15% to 1.0%, or 0.2% to 0.8%.

[0025] In some embodiments of the present invention, the antibacterial agent in the illustrated composition comprises the following components in parts by weight: 0.06-0.70 parts of chlorhexidine acetate and 0.01-0.20 parts of chitosan, for example, 0.08-0.65 parts of chlorhexidine acetate and 0.02-0.15 parts of chitosan, for example, 0.10-0.60 parts of chlorhexidine acetate and 0.03-0.10 parts of chitosan.

[0026] In some embodiments of the present invention, the composition may further comprise an inducer, which comprises or is selected from any one or any combination thereof of human epidermal growth factor and Lycium barbarum polysaccharide. In some embodiments of the present invention, the Lycium barbarum polysaccharide accounts for 1% to 20% by weight of the composition, for example 2% to 15%, 3% to 12%, 5.0% to 10.0%; the amount of human epidermal growth factor relative to the Lycium barbarum polysaccharide is 10 IU / Kg to 300 IU / Kg, for example 15 IU / Kg to 250 IU / Kg, 20 IU / Kg to 200 IU / Kg, or 30 IU / Kg to 150 IU / Kg.

[0027] In some embodiments of the invention, the polyol comprises glycerol, mannitol, and sorbitol, or comprises glycerol and mannitol. In some embodiments of the invention, the polyol accounts for 0.1% to 10% of the composition by weight, for example 0.2% to 8%, 0.5% to 5%, 0.7% to 3%, or 1% to 2%.

[0028] In some embodiments of the present invention, the polyol in the illustrated composition comprises the following components in parts by weight: 0.40-0.85 parts glycerol and 0.05-0.40 parts mannitol; or 0.45-0.80 parts glycerol and 0.01-0.35 parts mannitol; or 0.38-0.76 parts glycerol and 0.02-0.30 parts mannitol; or 0.40-0.85 parts glycerol, 0.015-0.40 parts mannitol and 0.40-0.80 parts sorbitol; or 0.45-0.80 parts glycerol, 0.01-0.35 parts mannitol and 0.45-0.75 parts sorbitol; or 0.38-0.76 parts glycerol, 0.02-0.30 parts mannitol and 0.50-0.70 parts sorbitol.

[0029] In some embodiments of the present invention, the activator is honey and / or glucose. In some embodiments of the present invention, the activator is honey. In some embodiments of the present invention, the activator is glucose. In some embodiments of the present invention, the activator is, for example, honey comprising 5%-45%, 10-40%, or 15%-35% of the composition by weight, or glucose comprising 3%-20%, 5%-15%, or 7.5%-10% of the composition by weight.

[0030] In some embodiments of the present invention, the composition comprises the following components in parts by weight:

[0031] Carrageenan 0.25; Xanthan gum 0.5; Konjac gum 0.1; Chlorhexidine acetate 0.2; Chitosan 0.03; Lycium barbarum polysaccharide 10; Glycerin 0.38; Mannitol 0.2; Sorbitol 0.5; Honey 25; and

[0032] Human epidermal growth factor, which is 300 IU relative to 10 kg of wolfberry polysaccharide;

[0033] or

[0034] Carrageenan 0.15; Xanthan gum 0.35; Konjac gum 0.2; Chlorhexidine acetate 0.3; Chitosan 0.04; Lycium barbarum polysaccharide 5; Glycerin 0.50; Mannitol 0.1; Sorbitol 0.6; Honey 30; and

[0035] Human epidermal growth factor, which is 667 IU relative to 10 kg of wolfberry polysaccharide;

[0036] or

[0037] Carrageenan 0.16; Xanthan gum 0.36; Konjac gum 0.15; Chlorhexidine acetate 0.1; Chitosan 0.05; Lycium barbarum polysaccharide 6; Glycerin 0.63; Mannitol 0.3; Sorbitol 0.7; Honey 15; and

[0038] Human epidermal growth factor, which is 667 IU relative to 10 kg of wolfberry polysaccharide;

[0039] or

[0040] Carrageenan 0.17; Xanthan gum 0.37; Konjac gum 0.3; Chlorhexidine acetate 0.5; Chitosan 0.025; Lycium barbarum polysaccharide 5.5; Glycerin 0.45; Mannitol 0.015; Sorbitol 0.55; Honey 31; and

[0041] Human epidermal growth factor, which is 636 IU relative to 10 kg of wolfberry polysaccharide;

[0042] or

[0043] Carrageenan 0.16; Xanthan gum 0.32; Konjac gum 0.25; Chlorhexidine acetate 0.4; Chitosan 0.063; Lycium barbarum polysaccharide 5.2; Glycerin 0.39; Mannitol 0.02; Sorbitol 0.65; Honey 35; and

[0044] Human epidermal growth factor, which is 481 IU relative to 10 kg of wolfberry polysaccharide;

[0045] or

[0046] Carrageenan 0.19g; Xanthan gum 0.4g; Konjac gum 0.45g; Chlorhexidine acetate 0.4g; Chitosan 0.09g; Lycium barbarum polysaccharide 6.2g; Glycerin 0.50g; Mannitol 0.075g; Sorbitol 0.57g; Honey 33g; and

[0047] Human epidermal growth factor, which is 726 IU relative to 10 kg of wolfberry polysaccharide;

[0048] or

[0049] Carrageenan 0.17; Xanthan gum 0.48; Konjac gum 0.32; Chlorhexidine acetate 0.6; Chitosan 0.018; Lycium barbarum polysaccharide 5.1; Glycerin 0.76; Mannitol 0.045; Sorbitol 0.7; Honey 31; and

[0050] Human epidermal growth factor, which is 1275 IU relative to 10 kg of wolfberry polysaccharide;

[0051] or

[0052] Carrageenan 0.1; Xanthan gum 0.41; Konjac gum 0.1; Chlorhexidine acetate 0.2; Chitosan 0.03; Glycerin 0.38; Mannitol 0.2; Honey 25;

[0053] or

[0054] Carrageenan 0.2; Xanthan gum 0.45; Konjac gum 0.1; Chlorhexidine acetate 0.15; Chitosan 0.03; Glycerin 0.38; Mannitol 0.2; Honey 25;

[0055] or

[0056] Carrageenan 0.25; Xanthan gum 0.45; Konjac gum 0.1; Chlorhexidine acetate 0.15; Chitosan 0.03; Glycerin 0.25; Mannitol 0.25; Honey 25.

[0057] In some embodiments of the invention, the composition does not contain an inducer, such as human epidermal growth factor.

[0058] In some embodiments of the present invention, the composition does not contain honey.

[0059] In some embodiments of the present invention, the composition is in the form of a liquid formulation or a semi-solid formulation, such as a powder, spray, aerosol, solution, suspension, emulsion, lotion, coating, liniment, ointment, film, or gel.

[0060] In some embodiments of the invention, the composition further comprises water.

[0061] In another aspect of the invention, a method for preparing the composition of the invention is also provided, comprising the steps of mixing and stirring components A to E with water.

[0062] In another aspect of the invention, the use of the compositions of the invention in the preparation of a medicament for treating trauma is provided. The trauma may be, for example, physical injury, diabetic foot ulcer, or surgical and cosmetic trauma, such as burns, scalds, hypothermia, electrical injuries, radiation injuries, or mechanical injuries.

[0063] Accordingly, the present invention provides a method for treating trauma, comprising administering the composition of the present invention to a subject in need. The trauma may be, for example, physical injury, diabetic foot ulcer, or surgical and cosmetic trauma, such as burns, scalds, hypothermia injuries, electrical injuries, radiation injuries, or mechanical injuries.

[0064] In another aspect of the invention, the use of the compositions of the invention in the preparation of skin regeneration products is provided. Accordingly, the invention also provides a method for preparing skin regeneration products, comprising using the compositions of the invention.

[0065] In another aspect of the invention, the use of the compositions of the invention in the preparation of medical aesthetic products is provided. Accordingly, the invention also provides a method for preparing skin medical aesthetic products, including using the compositions of the invention.

[0066] In another aspect of the invention, a cosmetic method for achieving scarless healing of skin wounds is provided, comprising applying the composition of the invention to the wound.

[0067] The inventors have discovered that the combination of the present invention, especially the combination containing an inducer and an activator, can effectively achieve scarless healing with unexpected and significant improvements. Attached Figure Description

[0068] Figure 1 shows a photograph of a patient's skin before treatment with the composition prepared in Example 1 of this invention.

[0069] Figure 2 shows a photograph of a patient's skin 15 days after treatment with the composition prepared in Example 1 of this invention.

[0070] Figure 3 shows a photograph of a patient's skin 20 days after treatment with the composition prepared in Example 1 of this invention.

[0071] Figure 4 shows a photograph of a patient's skin before treatment with the composition prepared in Example 2 of this invention.

[0072] Figure 5 shows a photograph of a patient's skin 15 days after treatment with the composition prepared in Example 2 of this invention.

[0073] Figure 6 shows a photograph of a patient's skin 30 days after treatment with the composition prepared in Example 2 of this invention.

[0074] Figure 7 shows a photograph of a patient's skin 45 days after treatment with the composition prepared in Example 2 of this invention.

[0075] Figure 8 shows a photograph of a patient's skin before treatment with the composition prepared in Example 3 of this invention.

[0076] Figure 9 shows a photograph of a patient's skin 15 days after treatment with the composition prepared in Example 3 of this invention.

[0077] Figure 10 shows a photograph of a patient's skin 30 days after treatment with the composition prepared in Example 3 of this invention.

[0078] Figure 11 shows a photograph of a patient's skin 60 days after treatment with the composition prepared in Example 3 of this invention.

[0079] Figure 12 shows a photograph of a patient's skin one day after treatment with the composition prepared in Example 4 of this invention.

[0080] Figure 13 shows a photograph of a patient's skin 15 days after treatment with the composition prepared in Example 4 of this invention.

[0081] Figure 14 shows a photograph of a patient's skin 30 days after treatment with the composition prepared in Example 4 of this invention.

[0082] Figure 15 shows a photograph of a patient's skin before treatment with the composition prepared in Example 5 of this invention.

[0083] Figure 16 shows a photograph of a patient's skin 3 days after treatment with the composition prepared in Example 5 of this invention.

[0084] Figure 17 shows a photograph of a patient's skin 20 days after treatment with the composition prepared in Example 5 of this invention.

[0085] Figure 18 shows a photograph of a patient's skin 40 days after treatment with the composition prepared in Example 5 of this invention.

[0086] Figure 19 shows a photograph of rabbit skin after one day of treatment with the control composition.

[0087] Figure 20 shows a photograph of rabbit skin after 3 days of treatment with the control composition.

[0088] Figure 21 shows a photograph of rabbit skin after 15 days of treatment with the control composition.

[0089] Figure 22 shows a photograph of rabbit skin after 30 days of treatment with the control composition.

[0090] Figure 23 is a photograph of rabbit skin after one day of treatment with the composition of Example 6 prepared according to the present invention.

[0091] Figure 24 shows a photograph of rabbit skin after 7 days of treatment with the composition of Example 6 prepared according to the present invention.

[0092] Figure 25 shows a photograph of rabbit skin after 15 days of treatment with the composition of Example 6 prepared according to the present invention.

[0093] Figure 26 is a photograph of rabbit skin after 30 days of treatment with the composition of Example 6 prepared according to the present invention.

[0094] Figure 27 is a photograph of the skin of a male mouse 1 after 7 days of treatment with the composition of Example 7 prepared according to the present invention.

[0095] Figure 28 is a photograph of the skin of a male mouse 1 after 11 days of treatment with the composition of Example 7 prepared according to the present invention.

[0096] Figure 29 is a photograph of the skin of a male mouse 1 after 15 days of treatment with the composition of Example 7 prepared according to the present invention.

[0097] Figure 30 is a photograph of the skin of male rat 2 after 7 days of treatment with the composition of Example 7 prepared according to the present invention.

[0098] Figure 31 is a photograph of the skin of male rat 2 after 11 days of treatment with the composition of Example 7 prepared according to the present invention.

[0099] Figure 32 is a photograph of the skin of male rat 2 after 15 days of treatment with the composition of Example 7 prepared according to the present invention.

[0100] Figure 33 is a photograph of the skin of male rat 3 after 7 days of treatment with the composition of Example 7 prepared according to the present invention.

[0101] Figure 34 is a photograph of the skin of male rat 3 after 11 days of treatment with the composition of Example 7 prepared according to the present invention.

[0102] Figure 35 is a photograph of the skin of male rat 3 after 15 days of treatment with the composition of Example 7 prepared according to the present invention.

[0103] Figure 36 is a photograph of a patient's skin before treatment with the composition of Preparation Example 8 of the present invention.

[0104] Figure 37 shows a photograph of a patient's skin 10 days after treatment with the composition of Preparation Example 8 of the present invention.

[0105] Figure 38 shows a photograph of a patient's skin 30 days after treatment with the composition of Preparation Example 8 of the present invention.

[0106] Figure 39 shows a photograph of a patient's skin 40 days after treatment with the composition of Preparation Example 8 of the present invention.

[0107] Figure 40 is a photograph of a patient's skin before treatment with the composition of Preparation Example 9 of the present invention.

[0108] Figure 41 is a photograph of a patient's skin 15 days after treatment with the composition of Preparation Example 9 of the present invention.

[0109] Figure 42 shows a photograph of a patient's skin 30 days after treatment with the composition of Preparation Example 9 of the present invention.

[0110] Figure 43 is a photograph of a patient's skin before treatment with the composition of Preparation Example 10 of the present invention.

[0111] Figure 44 is a photograph of a patient's skin 15 days after treatment with the composition of Preparation Example 10 of the present invention.

[0112] Figure 45 shows a photograph of a patient's skin 30 days after treatment with the composition of Preparation Example 10 of the present invention. Detailed Implementation

[0113] The present invention is further described below with reference to embodiments, but these embodiments are not intended to limit the scope of the invention.

[0114] Terms and definitions:

[0115] The term "semi-solid formulation" as used in this article refers to a formulation with appropriate consistency and fluidity that is between liquid and solid, formed by mixing a drug with a matrix, such as ointments, emulsions, coatings, films, gels, and adhesives.

[0116] The term "injury" as used in this article refers to the destruction of tissue structure and / or dysfunction caused by the action of a wounding substance or factor on the body. The term "physical injury" as used in this article refers to bodily injury caused by physical factors such as freezing, burns, electric shock, knives, gunshot wounds, sports, radiation, ultrasound, ultraviolet radiation, and mechanical force. The term "mechanical injury" as used in this article refers to bodily injury caused by mechanical force, that is, the destruction of organ and tissue structure and / or dysfunction caused by the mechanical force of a wounding substance, excluding injuries caused by high temperature, low temperature, electric current, lightning strikes, radiation, and poisoning.

[0117] In this study, the dosage or concentration of epidermal growth factor was expressed in International Units (IU) based on biological activity. Specifically, the ED50, determined by dose-dependent proliferation assay of BALB / 3T3 cells, was 0.99 ng / mL, corresponding to 1.01 x 10⁻⁶. 6 Specific activity of IU / mg.

[0118] In this article, "surgical incision" refers to a wound or incision left on the skin surface due to a surgical procedure.

[0119] Unless otherwise specified, percentages mentioned in this application refer to weight ratios.

[0120] Considering weighing errors and technical requirements, such as deviations within 10% of the nominal value, these deviations are still considered to be within the scope of protection of this application. For example, deviations within 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, and 1% are still considered to be within the scope of protection of this application.

[0121] The compositions and methods of this invention can be used in multiple medical fields, including burns, diabetic foot ulcers, and cosmetic medicine. For example, the compositions and methods of this invention can be used for third-degree burns without skin grafting. The compositions and methods of this invention can be used for diabetic foot ulcers without amputation. The compositions and methods of this invention can be used for surgical incisions to achieve scarless healing. The compositions and methods of this invention can also be used in cosmetic medicine to improve skin appearance.

[0122] In some embodiments, the present invention provides compositions in the following content ranges.

[0123] Based on the weight percentage of the raw materials, the present invention provides a composition with the following formulation:

[0124] Humectants: Carrageenan 0.15%-0.7%; Xanthan gum 0.35%-1%; Konjac gum 0.1%-0.8%;

[0125] Antibacterial agents: chlorhexidine acetate 0.1%-0.9%; chitosan 0.02%-0.09%;

[0126] Inducing agent: Lycium barbarum polysaccharide 5%-15%; human epidermal growth factor relative to the Lycium barbarum polysaccharide is 10 IU / kg Lycium barbarum polysaccharide to 300 IU / kg Lycium barbarum polysaccharide, for example 15 IU / kg Lycium barbarum polysaccharide to 250 IU / kg Lycium barbarum polysaccharide, 20 IU / kg Lycium barbarum polysaccharide to 200 IU / kg Lycium barbarum polysaccharide or 30 IU / kg Lycium barbarum polysaccharide to 150 IU / kg Lycium barbarum polysaccharide;

[0127] Polyols: Glycerin 3.8%-12.6%; Mannitol 0.01%-0.2%; Sorbitol 0.5%-2.0%;

[0128] Activator: 10%-50% honey;

[0129] Water: Add to 100%.

[0130] In other embodiments, the present invention provides compositions in the following content ranges.

[0131] Based on the weight percentage of the raw materials, the present invention provides a composition with the following formulation:

[0132] Humectants: Carrageenan 0.15%-0.7%; Xanthan gum 0.35%-1%; Konjac gum 0.1%-0.8%;

[0133] Antibacterial agents: chlorhexidine acetate 0.1%-0.9%; chitosan 0.02%-0.09%;

[0134] Polyols: Glycerin 3.8%-12.6%; Mannitol 0.01%-0.2%; Sorbitol 0.5%-2.0%;

[0135] Activator: 10%-50% glucose solution;

[0136] Water: Add to 100%.

[0137] The present invention also provides a general method for preparing the following compositions of the present invention, comprising the following steps:

[0138] Step 1 - Slowly add all components except the activator to the water, stir at an appropriate speed (e.g., 400 rpm), stir for a certain period of time (e.g., 30 minutes), add the ingredients in multiple batches, and finally mix them to obtain the first mixture;

[0139] Step 2 - Add the activator to the first mixture and stir at an appropriate speed (e.g., 100 revolutions per minute) for a certain period of time (e.g., 30 minutes) to obtain the composition of the present invention.

[0140] In some preferred embodiments, the preparation of the composition of the present invention further includes step 3 - bottling, packaging, and sterilization.

[0141] The method of application of the composition of the present invention is as follows: apply directly to the wound, 3-4 times a day, until the wound heals.

[0142] The composition of the present invention is for external use, preferably sprayed or applied directly to the wound site, extending about 1 cm beyond the perimeter, and applied 3-4 times daily.

[0143] Compared with the prior art, the composition of the present invention has at least one of the following beneficial effects: 1. No inflammatory reaction after trauma; 2. No obvious bacterial infection in the wound; 3. No contraction around the wound; 4. No obvious fibrotic connective tissue hyperplasia in the wound; 5. No scarring after wound healing.

[0144] The technical solution of the present invention will be further described in detail below with reference to specific embodiments.

[0145] The following descriptions are based on the formulations and preparation methods in Preparation Examples 1-10.

[0146] Preparation Example 1

[0147] Formula: Carrageenan 0.25kg; Xanthan gum 0.5kg; Konjac gum 0.1kg; Chlorhexidine acetate 0.2kg; Chitosan 0.03kg; Human epidermal growth factor 300IU; Lycium barbarum polysaccharide 10kg; Glycerin 300ml; Mannitol 0.2kg; Sorbitol 0.5kg; Honey 25kg; Purified water to 100kg.

[0148] Specific steps of the preparation method:

[0149] Step 1 - Except for honey, slowly add all other ingredients to purified water, stirring at 400 rpm for 30 minutes. Add the ingredients in multiple batches, and finally mix them together to obtain the first mixture.

[0150] Step 2 - Add honey to the first mixture and stir at 100 revolutions per minute for 30 minutes to obtain the finished product.

[0151] Preparation Example 2

[0152] Formula: Carrageenan 0.15kg; Xanthan gum 0.35kg; Konjac gum 0.2kg; Chlorhexidine acetate 0.3kg; Chitosan 0.04kg; Human epidermal growth factor 600IU; Lycium barbarum polysaccharide 5kg; Glycerin 400ml; Mannitol 0.1kg; Sorbitol 0.6kg; Honey 30kg; Purified water to 100kg.

[0153] Specific steps of the preparation method:

[0154] Step 1 - Except for honey, slowly add all other ingredients to purified water, stirring at 400 rpm for 30 minutes. Add the ingredients in multiple batches, and finally mix them together to obtain the first mixture.

[0155] Step 2 - Add honey to the first mixture and stir at 100 revolutions per minute for 30 minutes to obtain the finished product.

[0156] Preparation Example 3

[0157] Formula: Carrageenan 0.16kg; Xanthan gum 0.36kg; Konjac gum 0.15kg; Chlorhexidine acetate 0.1kg; Chitosan 0.05kg; Human epidermal growth factor 400IU; Lycium barbarum polysaccharide 6kg; Glycerin 500ml; Mannitol 0.3kg; Sorbitol 0.7kg; Honey 15kg; Purified water to 100kg.

[0158] Specific steps of the preparation method:

[0159] Step 1 - Except for honey, slowly add all other ingredients to purified water, stirring at 400 rpm for 30 minutes. Add the ingredients in multiple batches, and finally mix them together to obtain the first mixture.

[0160] Step 2 - Add honey to the first mixture and stir at 100 revolutions per minute for 30 minutes to obtain the finished product.

[0161] Preparation Example 4

[0162] Formula: Carrageenan 0.17kg; Xanthan gum 0.37kg; Konjac gum 0.3kg; Chlorhexidine acetate 0.5kg; Chitosan 0.025kg; Human epidermal growth factor 350IU; Lycium barbarum polysaccharide 5.5kg; Glycerin 360ml; Mannitol 0.015kg; Sorbitol 0.55kg; Honey 31kg; Purified water to 100kg.

[0163] Specific steps of the preparation method:

[0164] Step 1 - Except for honey, slowly add all other ingredients to purified water, stirring at 400 rpm for 30 minutes. Add the ingredients in multiple batches, and finally mix them together to obtain the first mixture.

[0165] Step 2 - Add honey to the first mixture and stir at 100 revolutions per minute for 30 minutes to obtain the finished product.

[0166] Preparation Example 5

[0167] Formula: Carrageenan 0.16kg; Xanthan gum 0.32kg; Konjac gum 0.25kg; Chlorhexidine acetate 0.4kg; Chitosan 0.063kg; Human epidermal growth factor 250IU; Lycium barbarum polysaccharide 5.2kg; Glycerin 310ml; Mannitol 0.02kg; Sorbitol 0.65kg; Honey 35kg; Purified water to 100kg.

[0168] Specific steps of the preparation method:

[0169] Step 1 - Except for honey, slowly add all other ingredients to purified water, stirring at 400 rpm for 30 minutes. Add the ingredients in multiple batches, and finally mix them together to obtain the first mixture.

[0170] Step 2 - Add honey to the first mixture and stir at 100 revolutions per minute for 30 minutes to obtain the finished product.

[0171] Preparation Example 6

[0172] Formula: Carrageenan 0.19kg; Xanthan gum 0.4kg; Konjac gum 0.45kg; Chlorhexidine acetate 0.4kg; Chitosan 0.09kg; Human epidermal growth factor 450IU; Lycium barbarum polysaccharide 6.2kg; Glycerin 400ml; Mannitol 0.075kg; Sorbitol 0.57kg; Honey 33kg; Purified water to 100kg.

[0173] Specific steps of the preparation method:

[0174] Step 1 - Except for honey, slowly add all other ingredients to purified water, stirring at 400 rpm for 30 minutes. Add the ingredients in multiple batches, and finally mix them together to obtain the first mixture.

[0175] Step 2 - Add honey to the first mixture and stir at 100 revolutions per minute for 30 minutes to obtain the finished product.

[0176] Preparation Example 7

[0177] Formula: Carrageenan 0.17kg; Xanthan gum 0.48kg; Konjac gum 0.32kg; Chlorhexidine acetate 0.6kg; Chitosan 0.018kg; Human epidermal growth factor 650IU; Lycium barbarum polysaccharide 5.1kg; Glycerin 600ml; Mannitol 0.045kg; Sorbitol 0.7kg; Honey 31kg; Purified water to 100kg.

[0178] Specific steps of the preparation method:

[0179] Step 1 - Except for honey, slowly add all other ingredients to purified water, stirring at 400 rpm for 30 minutes. Add the ingredients in multiple batches, and finally mix them together to obtain the first mixture.

[0180] Step 2 - Add honey to the first mixture and stir at 100 revolutions per minute for 30 minutes to obtain the finished product.

[0181] Preparation Example 8

[0182] Formula: Carrageenan 0.1kg; Xanthan gum 0.41kg; Konjac gum 0.1kg; Chlorhexidine acetate 0.2kg; Chitosan 0.03kg; Glycerin 300ml; Mannitol 0.2kg; 20% glucose solution 25kg; Purified water to 100kg.

[0183] Specific steps of the preparation method:

[0184] Step 1 - Except for the glucose solution, slowly add all other raw materials to the purified water, stirring at 400 rpm for 30 minutes. Add the materials in multiple batches, and finally mix them together to obtain the first mixture.

[0185] Step 2 - Add the glucose solution to the first mixture and stir at 100 revolutions per minute for 30 minutes to obtain the finished product.

[0186] Preparation Example 9

[0187] Formula: Carrageenan 0.2kg; Xanthan gum 0.45kg; Konjac gum 0.1kg; Chlorhexidine acetate 0.15kg; Chitosan 0.03kg; Glycerin 300ml; Mannitol 0.2kg; 30% glucose solution 25kg; Purified water to 100kg.

[0188] Specific steps of the preparation method:

[0189] Step 1 - Except for the glucose solution, slowly add all other raw materials to the purified water, stirring at 400 rpm for 30 minutes. Add the materials in multiple batches, and finally mix them together to obtain the first mixture.

[0190] Step 2 - Add the glucose solution to the first mixture and stir at 100 revolutions per minute for 30 minutes to obtain the finished product.

[0191] Preparation Example 10

[0192] Formula: Carrageenan 0.25kg; Xanthan gum 0.45kg; Konjac gum 0.1kg; Chlorhexidine acetate 0.15kg; Chitosan 0.03kg; Glycerin 200ml; Mannitol 0.25kg; 40% glucose solution 25kg; Purified water to 100kg.

[0193] Specific steps of the preparation method:

[0194] Step 1 - Except for the glucose solution, slowly add all other raw materials to the purified water, stirring at 400 rpm for 30 minutes. Add the materials in multiple batches, and finally mix them together to obtain the first mixture.

[0195] Step 2 - Add the glucose solution to the first mixture and stir at 100 revolutions per minute for 30 minutes to obtain the finished product.

[0196] Effect Example

[0197] Example 1:

[0198] A 70-year-old male patient suffered a burn to his right ankle with boiling water. He had previously sought treatment at two hospitals, but the wound failed to heal. During the experiment of this invention, it was found that the wound on his right ankle had developed a purulent infection, a typical third-degree burn. After 30 days of treatment with the product of Preparation Example 1, the wound healed without scarring. Skin photographs of the patient before treatment, and 15 and 20 days after treatment with the product of Example 1 of this invention, are shown in Figures 1-3. It is evident that after 20 days of treatment with the composition of this invention, the patient's wound had almost healed without scarring.

[0199] Example 2:

[0200] A 60-year-old male patient presented with a diabetic foot ulcer on his left lower extremity. The wound had developed severe purulent infection, and the ulcer measured 10 × 6 cm. 2 The hospital recommended amputation. After 45 days of treatment with the product of Example 2, the wound infection significantly improved, pink granulation tissue was visible, and the ulcer area shrank considerably. Skin photographs of the patient before treatment and after treatment with the product of Example 2 of this invention at different times are shown in Figures 4-7. It can be seen that before treatment, the patient's wound was severely necrotic, and the ulcer area had reached 10 × 6 cm. 2After 15 days of treatment with the product of Example 2 of the present invention, the purulent infection of the wound disappeared and the wound area shrank; after 30 days of treatment, purplish-red granulation tissue appeared in the wound; after 45 days of treatment, pink granulation tissue appeared in the wound, the wound healed well, and amputation was no longer necessary.

[0201] Example 3:

[0202] A 50-year-old female patient suffered a low-temperature burn on her right lower back after using a hand warmer due to hemiplegia and impaired skin sensation. The wound ulcerated, with an area of ​​approximately 10 x 8 cm. 2 The ulcer was slow to heal and required surgical skin grafting to reach its full size. After 15 days of treatment with the product from Example 3, the wound showed slight shrinkage and reduced infection; after 30 days, the wound significantly shrank, and the surrounding skin nearly returned to normal; after 60 days, most of the wound had healed almost without scarring (see Figures 8-11). This example demonstrates that even large-area ulcers treated with the composition of this invention do not require surgical skin grafting.

[0203] Example 4:

[0204] A 45-year-old male patient suffered a left clavicle fracture and began treatment with the product of Example 4 on the same day after surgery. One day after treatment, there was no inflammatory reaction in the wound, and pluripotent stem cells resembling "bud bases" appeared in the center of the wound; after 15 days of treatment, the wound was basically healed with no obvious scar formation; after 30 days of treatment, the wound was almost scarless (see Figures 12-14).

[0205] This demonstrates that the product is effective for postoperative surgical incisions and can be used in postoperative rehabilitation and cosmetic procedures.

[0206] Example 5:

[0207] The inventor is a 69-year-old male. To demonstrate scarless wound healing, a 2cm burn was inflicted on the right wrist joint with a cigarette butt, resulting in a wound area of ​​approximately 1cm. 2 This resulted in third-degree burns. After 3 days of treatment with the product from Preparation Example 5, no inflammation or infection was observed in the wound; after 20 days of treatment, the wound surface disappeared and healed well; after 40 days of treatment, the wound healed without scarring (see Figures 15-18).

[0208] Example 6 - Rabbit Experiment

[0209] Rabbit animal experiment: Male rabbits, weighing 3.5 kg each, were divided into two groups. Group 1 was the control group, treated with conventional methods (dressing changed once daily); Group 2 was the treatment group using the composition of this invention, treated with the product of Preparation Example 6 (applied three times daily). Results showed that in control group 1, scar tissue formation was observed on postoperative day 15. In group 2, treated with the composition of this invention, the wound was nearly scarless by postoperative day 30 (see Figures 19-26).

[0210] Example 7 - Rat Experiment

[0211] Three male rats, each weighing 350-400g, suffered third-degree burns with a soldering iron, the burn area being approximately 2.5 × 2.5 cm. 2 Each rat was treated with the product of Preparation Example 7 of the present invention, applied once every 2 hours, for 12 times a day. Photos taken on days 7, 11, and 15 after treatment confirmed that none of the three rats showed any inflammatory response, bacterial infection, or fibrous connective tissue hyperplasia. The epidermal wounds did not shrink, and pink epidermal tissue was visible after 15 days (see Figures 27-35).

[0212] Example 8:

[0213] An 8-year-old male patient received treatment 10 days after suffering a burn. The wound area was approximately 3*4 cm², resulting in a third-degree burn (see Figure 36 for a pre-treatment photograph showing eschar formation). After 10 days of treatment with the product from Preparation Example 8, the wound was basically healed, appearing pink, with new epithelial regeneration. After 30 days of treatment, wound healing was observed. After 40 days of treatment, pink epithelial tissue was visible on the skin, indicating near-scarless healing (see Figures 36-39).

[0214] Example 9:

[0215] A 48-year-old male patient presented with a left clavicle fracture and began treatment with the product of Example 9 7 days post-surgery. The wound showed no inflammatory reaction; after 15 days of treatment, the wound was dry, without infection, and pink epithelium was visible, revealing the surgical incision; after 30 days of treatment, very slight scar tissue was visible on the surgical wound (see Figures 40-42).

[0216] Example 10:

[0217] A 40-year-old male patient underwent appendectomy and began treatment with the product of Example 10 on the same day after the surgery. No inflammatory reaction was observed in the wound afterward; 15 days after treatment, pink epithelium appeared in the wound, revealing the surgical incision; 30 days after treatment, very slight scar tissue was visible in the surgical wound (see Figures 43-42).

[0218] In this invention, animal experiments were conducted on 30 males (weighing 350g-400g each), with 27 cases showing near-scarless healing, resulting in a near-scarless healing rate of 90%. Specifically, the formulation used in Preparation Example 1 was employed in 3 cases, Preparation Example 2 in 7 cases, Preparation Example 3 in 2 cases, Preparation Example 4 in 3 cases, Preparation Example 5 in 5 cases, Preparation Example 6 in 1 case, Preparation Example 7 in 5 cases, Preparation Example 8 in 2 cases, Preparation Example 9 in 1 case, and Preparation Example 10 in 1 case.

[0219] In this invention, a clinical trial was conducted on 30 cases, including 16 males aged 6-60 years and 14 females aged 10-70 years. Near-scarless healing was achieved in 27 cases, representing a near-scarless healing rate of 90%. Among these, 5 cases used the formulation from Preparation Example 1, 5 cases used the formulation from Preparation Example 2, 1 case used the formulation from Preparation Example 3, 1 case used the formulation from Preparation Example 4, 5 cases used the formulation from Preparation Example 5, 6 cases used the formulation from Preparation Example 6, 4 cases used the formulation from Preparation Example 7, 1 case used the formulation from Preparation Example 8, 1 case used the formulation from Preparation Example 9, and 1 case used the formulation from Preparation Example 10.

Claims

1. A composition for skin regeneration comprising the following components: A. a humectant, preferably selected from any one of and any combination of carrageenan, xanthan gum and konjac gum; B. an antibacterial agent, preferably selected from any one of and any combination of chlorhexidine acetate and chitosan; C. a polyol, preferably selected from any one of and any combination of glycerol, mannitol and sorbitol, for example selected from glycerol and mannitol; and D. an activator selected from any one of and any combination of honey and glucose.

2. The composition according to claim 1, wherein the humectant comprises carrageenan, xanthan gum and konjac gum.

3. The composition according to claim 1 or 2, wherein the humectant comprises 0.1% to 5.0%, for example 0.1% to 5.0%, 0.2% to 4.0%, 0.3% to 3.0%, 0.5% to 3.0%, 0.6% to 2.5%, 0.8% to 2.0% by weight of the composition.

4. The composition according to any one of claims 1 to 3, wherein the humectant comprises the following components by weight: carrageenan 0.05-0.35, xanthan gum 0.20-0.60 and konjac gum 0.05-0.55, for example carrageenan 0.10-0.30, xanthan gum 0.25-0.55 and konjac gum 0.07-0.50, for example carrageenan 0.15-0.25, xanthan gum 0.32-0.48 and konjac gum 0.1-0.

45.

5. The composition according to any one of claims 1 to 4, wherein the antibacterial agent comprises chlorhexidine acetate and chitosan.

6. The composition according to any one of claims 1 to 5, wherein the antibacterial agent comprises 0.05% to 2.0%, for example 0.1% to 1.5%, 0.15% to 1.0%, 0.2% to 0.8% by weight of the composition.

7. The composition according to any one of claims 1 to 6, wherein the antibacterial agent comprises the following components by weight: chlorhexidine acetate 0.06-0.70 and chitosan 0.01-0.20, for example chlorhexidine acetate 0.08-0.65 and chitosan 0.02-0.15, for example chlorhexidine acetate 0.10-0.60 and chitosan 0.03-0.

10.

8. The composition according to any one of claims 1 to 7, wherein the polyol comprises 0.1% to 10%, for example 0.2% to 8%, 0.5% to 5%, 0.7% to 3% or 1% to 2% by weight of the composition.

9. The composition of any one of claims 1 to 8, wherein the polyol comprises the following parts by weight of components: glycerol 0.40-0.85, mannitol 0.05-0.40; or glycerol 0.45-0.80, mannitol 0.01-0.35; or glycerol 0.38-0.76, mannitol 0.02-0.30; or glycerol 0.40-0.85, mannitol 0.015-0.40 and sorbitol 0.40-0.80; or glycerol 0.45-0.80, mannitol 0.01-0.35 and sorbitol 0.45-0.75; or glycerol 0.38-0.76, mannitol 0.02-0.30 and sorbitol 0.50-0.

70.

10. The composition of any one of claims 1 to 9, wherein the activating agent is honey and / or glucose, for example, honey at 5%-45%, 10-40% or 15%-35% by weight of the composition; or glucose at 3%-20%, 5%-15% or 7.5%-10% by weight of the composition.

11. The composition of any one of claims 1 to 10, wherein the activating agent is at 5% to 60% by weight of the composition, for example, 8% to 55%, 10% to 50%, 12% to 40% or 15% to 35%.

12. The composition of any one of claims 1 to 11, further comprising an inducing agent, for example, the inducing agent is selected from any one of human epidermal growth factor and wolfberry polysaccharide, and any combination thereof.

13. The composition of claim 12, wherein the wolfberry polysaccharide is at 1% to 20% by weight of the composition, for example, 2% to 15%, 3% to 12%, 5.0% to 10.0%; and the human epidermal growth factor is at 10 IU / Kg to 300 IU / Kg relative to the amount of wolfberry polysaccharide, for example, 15 IU / Kg to 250 IU / Kg, 20 IU / Kg to 200 IU / Kg or 30 IU / Kg to 150 IU / Kg.

14. The composition of any one of claims 1 to 13, comprising the following parts by weight of components: carrageenan 0.25; xanthan gum 0.5; konjac gum 0.1; chlorhexidine acetate 0.2; chitosan 0.03; wolfberry polysaccharide 10; glycerol 0.38; mannitol 0.2; sorbitol 0.5; honey 25; and human epidermal growth factor at 300 IU per 10 kg of wolfberry polysaccharide; or carrageenan 0.15; xanthan gum 0.35; konjac gum 0.2; chlorhexidine acetate 0.3; chitosan 0.04; wolfberry polysaccharide 5; glycerol 0.50; mannitol 0.1; sorbitol 0.6; honey 30; and human epidermal growth factor at 667 IU per 10 kg of wolfberry polysaccharide; or carrageenan 0.16; xanthan gum 0.36; konjac gum 0.15; chlorhexidine acetate 0.1; chitosan 0.05; wolfberry polysaccharide 6; glycerol 0.63; mannitol 0.3; sorbitol 0.7; honey 15; and human epidermal growth factor at 1000 IU per 10 kg of wolfberry polysaccharide. ​ ​ ​ ​ ​ ​ ​ human epidermal growth factor, 667 IU per 10 kg of gypenosides; or carrageenan 0.17; xanthan gum 0.37; konjac gum 0.3; chlorhexidine acetate 0.5; chitosan 0.025; gypenosides 5.5; glycerol 0.45; mannitol 0.015; sorbitol 0.55; honey 31; and human epidermal growth factor, 636 IU per 10 kg of gypenosides; or carrageenan 0.16; xanthan gum 0.32; konjac gum 0.25; chlorhexidine acetate 0.4; chitosan 0.063; gypenosides 5.2; glycerol 0.39; mannitol 0.02; sorbitol 0.65; honey 35; and human epidermal growth factor, 481 IU per 10 kg of gypenosides; or carrageenan 0.19; xanthan gum 0.4; konjac gum 0.45; chlorhexidine acetate 0.4; chitosan 0.09; gypenosides 6.2; glycerol 0.50; mannitol 0.075; sorbitol 0.57; honey 33; and human epidermal growth factor, 726 IU per 10 kg of gypenosides; or carrageenan 0.17; xanthan gum 0.48; konjac gum 0.32; chlorhexidine acetate 0.6; chitosan 0.018; gypenosides 5.1; glycerol 0.76; mannitol 0.045; sorbitol 0.7; honey 31; and human epidermal growth factor, 1275 IU per 10 kg of gypenosides; or carrageenan 0.1; xanthan gum 0.41; konjac gum 0.1; chlorhexidine acetate 0.2; chitosan 0.03; glycerol 0.38; mannitol 0.2; honey 25; or carrageenan 0.2; xanthan gum 0.45; konjac gum 0.1; chlorhexidine acetate 0.15; chitosan 0.03; glycerol 0.38; mannitol 0.2; honey 25; or carrageenan 0.25; xanthan gum 0.45; konjac gum 0.1; chlorhexidine acetate 0.15; chitosan 0.03; glycerol 0.25; mannitol 0.25; honey 25.

15. The composition according to any one of claims 1 to 14, which is in the form of a liquid preparation or a semi-solid preparation, such as a powder, a spray, an aerosol, a solution, a suspension, an emulsion, a lotion, a coating agent, a liniment, a paste, a film, a gel.

16. The composition according to any one of claims 1 to 15, which further comprises water, for example, water is the balance when the total of the composition is 100 parts by weight.

17. A method of preparing the composition according to any one of claims 1 to 16, comprising the step of mixing the components with water.

18. Use of the composition according to any one of claims 1 to 16 in the preparation of a medicament for the treatment of a wound, such as a medicament in the form of a liquid, a semi-solid or a dressing.

19. The use according to claim 18, wherein the wound is a physical injury, a diabetic foot ulcer, or a wound formed by surgery and medical cosmetology, such as a burn, a scald, a cold injury, an electric shock injury, a knife injury, a gun injury, a laceration, a radiation injury or a mechanical injury.

20. Use of a composition according to any one of claims 1 to 16 for the manufacture of a skin regenerative product, for example the product is in liquid form, semi-solid form or in the form of a dressing.

21. Use of a composition according to any one of claims 1 to 16 for the manufacture of a medical cosmetic product, for example the product is in liquid form, semi-solid form or in the form of a dressing.

22. A cosmetic method of treating skin comprising applying to the skin a composition according to any one of claims 1 to 16, for example the product is in liquid form, semi-solid form or in the form of a dressing.

Images